<div id="readability-page-1"><ul><li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li></ul><p>Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Investment analysts at William Blair lifted their FY2028 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a report released on Tuesday, September 2nd. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $5.67 for the year, up from their previous estimate of $5.61. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.</p><p>A number of other equities research analysts have also recently commented on the company. Morgan Stanley  restated a &#34;hold&#34; rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa America cut Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 5th. Wall Street Zen cut Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, June 6th. Daiwa Capital Markets cut Bristol Myers Squibb from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $42.00 target price on the stock. in a research report on Tuesday, August 5th. Finally, Citigroup dropped their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, August 1st. One analyst  has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned  a Hold rating and one  has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $56.38.</p><div><p><span></span><span>Get <strong>Bristol Myers Squibb</strong> alerts:</span></p></div><ul><li>MarketBeat Week in Review – 02/03 - 02/07</li></ul><p><b>View Our Latest Stock Report on Bristol Myers Squibb</b></p><h2>Bristol Myers Squibb Price Performance</h2><p>NYSE:BMY opened at $47.48 on Thursday. Bristol Myers Squibb has a 52 week low of $42.96 and a 52 week high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The stock has a market capitalization of $96.64 billion, a PE ratio of 19.14, a price-to-earnings-growth ratio of 2.41 and a beta of 0.35. The stock's 50-day moving average price is $47.08 and its 200-day moving average price is $50.61. </p><ul><li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li></ul><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm's revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the firm earned $2.07 EPS.  Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.</p><h2>Bristol Myers Squibb Announces Dividend</h2><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.2%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's payout ratio is presently 100.00%. </p><h2>Insider Transactions at Bristol Myers Squibb</h2><p>In related news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own  0.07% of the company's stock. </p><h2>Institutional Investors Weigh In On Bristol Myers Squibb</h2><p>Several institutional investors have recently bought and sold shares of BMY. Brighton Jones LLC lifted its stake in  Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after purchasing an additional 4,935 shares in the last quarter.  Bank Pictet &amp; Cie Europe AG purchased a new position in  Bristol Myers Squibb in the 4th quarter worth approximately $13,094,000.  Cary Street Partners Financial LLC purchased a new position in  Bristol Myers Squibb in the 4th quarter worth approximately $2,301,000.  BOKF NA lifted its stake in  Bristol Myers Squibb by 1.4% in the 4th quarter. BOKF NA now owns 103,029 shares of the biopharmaceutical company's stock worth $5,752,000 after purchasing an additional 1,464 shares in the last quarter.  Finally, Centiva Capital LP lifted its stake in  Bristol Myers Squibb by 8.7% in the 4th quarter. Centiva Capital LP now owns 19,671 shares of the biopharmaceutical company's stock worth $1,113,000 after purchasing an additional 1,580 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Bristol Myers Squibb</h2> (Get Free Report)<p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><h2>Read More</h2><ul><li>Five stocks we like better than Bristol Myers Squibb</li><li>Investing in the High PE Growth Stocks </li><li>Return of the ETFs: 3 Names That Could Keep Outperforming</li><li>What is a support level?</li><li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li><li>Best Energy Stocks - Energy Stocks to Buy Now</li><li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Investment analysts at William Blair have raised their FY2028 earnings per share (EPS) estimate for Bristol Myers Squibb (NYSE:BMY) from $5.61 to $5.67. The consensus estimate for the company's current full-year earnings is $6.74 per share. Various analysts have recently adjusted their ratings on the stock, with one strong buy, four buys, fifteen holds, and one sell. The stock opened at $47.48, with a market cap of $96.64 billion and a PE ratio of 19.14. Bristol Myers Squibb also announced a quarterly dividend of $0.62, yielding 5.2%.</p>

Research Analysts Issue Forecasts for BMY FY2028 Earnings